Global Blood Therapeutics (GBT) Announces Upcoming Data Presentations Supporting Voxelotor SCD Program

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that four abstracts related to the voxelotor program in sickle cell disease will be presented during the Foundation for Sickle Cell Disease Research’s (FSCDR) 12th Annual SCD Research and Educational Symposium in Washington, D.C., taking place June 15-17, 2018. Four encore abstracts have been accepted, including three for oral presentation. Additionally, Kenneth R. Bridges, M.D., vice president, medical affairs at GBT, will be discussing voxelotor as part of the Investigational New Drugs, Therapeutic and Device Symposium on Friday, June 15, from 4:30-6:30 p.m. Eastern Time (ET).

The abstracts are now available for symposium attendees through the FSCDR 2018 app. The app is available for download for both iPhones and Androids. Details regarding the abstracts are as follows:

Sunday, June 17

Oral Presentation: Breakout SessionAbstract: Opioid Utilization Patterns in U.S. Individuals with Sickle Cell DiseaseTime: 1:45-3:15 p.m. ET

Oral Presentation: Breakout SessionAbstract: Access to Care for Medicaid and Commercially Insured U.S. Individuals with Sickle Cell DiseaseTime: 1:45-3:15 p.m. ET

Oral Presentation: Breakout SessionAbstract: Compassionate-Use Voxelotor (GBT440) for Patients with Severe Sickle Cell Disease (SCD) and Life-Threatening ComorbiditiesTime: 3:30-5:00 p.m. ET

Poster SessionAbstract: Novel Trial Design to Evaluate Oral Voxelotor for the Treatment of Sickle Cell Disease (SCD): the Phase 3 Hemoglobin Oxygen Affinity Modulation to Inhibit Sickle Hemoglobin Polymerization (HOPE) Trial (GBT440-031)Time: 5:15-6:30 p.m. ET

You May Also Be Interested In

• AstraZeneca (AZN), Daiichi Sankyo's ENHERTU approved in US as first HER2-directed therapy for patients with previously treated HER2-mutant metastatic NSCLC
• OneWater Marine Inc. (ONEW) Appoints Steve Roy to its Board
• AstraZeneca (AZN) Reports Enhertu Approved in US as First HER2-directed Yherapy for Patients with Previously Treated HER2-mutant Metastatic Non-small Cell Lung Cancer